Table 3 Demographics and clinical data of patients with procalcitonin (PCT) stopping advice treated adherently and non-adherently to the PCT protocol
Patients adherent to PCT stopping advice (n = 8) | Patients non-adherent to PCT stopping advice (n = 18) | p value | |
|---|---|---|---|
Age, years (median [IQR]) | 67 [59–75] | 68 [59–75] | 0.560 |
SAPS II score (median [IQR]) | 35 [31–43] | 44 [28–51] | 0.655 |
Male gender (% [95% CI]) | 50.0 [15.7–84.3] | 77.8 [30.6–69.4] | 0.197 |
ICU mortality (% [95% CI]) | 12.5 [0.3–52.7] | 33.3 [13.3–59.0] | 0.375 |
Ventilation hours (median [IQR]) | 353 [68–621] | 735 [209–1508] | 0.317 |
ICU LOS, days (median [IQR]) | 24 [3–38] | 23 [12–59] | 0.780 |
Hospital LOS, days (median [IQR]) | 57 [47–79] | 54 [34–100] | 0.824 |
SOFA score max (median [IQR]) | 11 [9–12] | 12 [9–13] | 0.557 |
Length of antibiotic treatment, days (median [IQR]) | 7 [6–9] | 12 [9–16] | 0.002 |
Antibiotic use density, DDD (median [IQR]) | 10 [7–12] | 18 [12–26] | 0.001 |
Initial PCT value, ng/mL (median [IQR]) | 20.0 [9.4–38.2] | 16.8 [2.0–42.7] | 0.560 |
Peak PCT value, ng/mL (median [IQR]) | 32.3 [9.4–64.2] | 44.9 [13.9–69.7] | 0.718 |
% [95% CI] (n) | % [95% CI] (n) | |
|---|---|---|
Cause of infection | ||
Abdominal sepsis | 87.5 [47.3–99.7] (7) | 44.4 [21.5–69.2] (8) |
Bloodstream infection | 0 | 0 |
Pleural empyema | 0 | 16.7 [3.5–41.4] (3) |
Pneumonia | 12.5 [0.3–52.7] (1) | 33.3 [13.3–59.0] (6) |
Prosthetic infection | 0 | 0 |
Urogenital sepsis | 0 | 5.6 [0.1–27] (1) |
Soft tissue infection | 0 | 0 |
Unknown | 0 | 0 |